MARKET

BCLI

BCLI

Brainstorm Cell Therapeutics I
NASDAQ
1.120
+0.145
+14.87%
After Hours: 1.138 +0.018 +1.63% 18:51 04/28 EDT
OPEN
0.9800
PREV CLOSE
0.9750
HIGH
1.270
LOW
0.9800
VOLUME
516.31K
TURNOVER
--
52 WEEK HIGH
10.05
52 WEEK LOW
0.7233
MARKET CAP
7.31M
P/E (TTM)
-0.4839
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 6h ago
Weekly Report: what happened at BCLI last week (0421-0425)?
Weekly Report · 11h ago
Weekly Report: what happened at BCLI last week (0414-0418)?
Weekly Report · 04/21 11:56
Weekly Report: what happened at BCLI last week (0407-0411)?
Weekly Report · 04/14 11:42
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 04/10 17:06
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 04/10 12:07
BrainStorm submits IND amendment to FDA for Phase 3b trial of NurOwn in ALS
TipRanks · 04/10 11:36
BrainStorm Cell Therapeutics Submits IND Amendment to FDA for Phase 3b Trial of NurOwn in Amyotrophic Lateral Sclerosis
Benzinga · 04/10 11:32
More
About BCLI
More
Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease; progressive multiple sclerosis (PMS); Alzheimer’s disease (AD); and other neurodegenerative diseases. Its NurOwn, a cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived MSCs to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. It has completed a Phase III pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells. The Company's wholly owned subsidiary, Brainstorm Cell Therapeutics Ltd. holds exclusive rights to commercialize NurOwn technology.
Recently
Symbol
Price
%Change

Webull offers Brainstorm Cell Therapeutics Inc stock information, including NASDAQ: BCLI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCLI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BCLI stock methods without spending real money on the virtual paper trading platform.